INTRODUCTION {#sec1-1}
============

Bone metastases are particularly common in patients with breast, prostate, and lung cancer.\[[@ref1]\] In 80% of the cases, bone metastases are located in several sites and can produce some complications, such as pathologic fracture, mainly femur and humerus; hypercalcemia (10% of cases); and spinal cord compression (5% of cases).\[[@ref2]\] Compared to the other conventional methods, such as use of analgesics and external beam radiotherapy, systematic palliative therapy using suitable bone-seeking radiopharmaceuticals have emerged as the most efficacious treatment modality for patients with multiple skeletal lesions.\[[@ref3][@ref4]\] The major challenge in developing effective radiopharmaceuticals for palliative treatment of bone pain due to skeletal metastasis is to deliver adequate dose of ionizing radiation at the skeletal lesion sites with minimum radiation-induced bone marrow suppression.\[[@ref5]\] Radioactive isotopes of phosphorus (^32^ P) and strontium (^89^ Sr) were the first radiopharmaceuticals used for treatment of skeletal metastases in patients.\[[@ref6][@ref7]\] Other beta-emitting radionuclides such as ^186^Re, ^153^Sm, ^177^Lu, ^117m^Sn, ^166^Ho, and ^175^Yb are recommended for this purpose.\[[@ref8][@ref9][@ref10][@ref11][@ref12][@ref13][@ref14]\] All agents have benefits and risks. The agents differ in terms of efficacy, duration of pain palliation, tumoricidal effects, ability to repeat treatments, toxicity, and other aspects.\[[@ref15]\]

Ytterbium-175 is one of radioisotopes that can be used for bone pain palliation. The thermal neutron cross-section of ^174^Yb is 63.2 barns.\[[@ref16]\] Therefore, it is possible to produce ^175^Yb in adequate specific activity using medium flux reactors. It decays by emission of beta particles 470 keV maximum energy (86.5%) to stable ^175^ Lu. The prominent gamma-rays emitted from ^175^Yb are 113.8 keV (1.88%), 286 keV (3.01%), and 396 keV (6.4%); these energies are suitable for imaging studies and low dose delivering for the patients.\[[@ref17]\] Also, the physical half-life of ^175^Yb is relatively longer (compared to ^153^Sm or ^166^Ho) and provide logistic advantages for facilitating supply to nuclear medicine centers far away from the reactors.

Multidentate polyaminopolyphosphonic acid ligands are known to form stable chelates with many metals including lanthanides. Among them, triethylenetetraminehexamethylene phosphonic acid (TTHMP) can be envisaged as an ideal carrier moiety, for the development of beta emitter-based radiopharmaceuticals, for bone palliation.\[[@ref18]\] In this research; preparation, quality control, and biodistribution study of ^175^Yb-TTHMP complex in animal model has been carried out.

MATERIALS AND METHODS {#sec1-2}
=====================

Natural ytterbium oxide was purchased from Isotec Inc, USA. All chemical components were obtained from Sigma-Aldrich Chemical Co. UK. All radioactivities counting related to paper chromatography were carried out by using a NaI (Tl) scintillation counter on adjustment of the baseline at 396 keV. The activity as well as the radionuclidic purity of the ^175^Yb produced was ascertained by gamma spectroscopy on the base of 396 keV peak by using the high-purity germanium (HPGe) detector and beta-spectroscopy was carried out by the Wallac 1220 Quantulus liquid scintillation spectrometer. Animal studies were performed in accordance with the United Kingdom Biological Council\'s Guidelines on the Use of Living Animals in Scientific Investigations. All the values were expressed as mean ± standard deviation (mean ± SD).

Production and quality control of ^175^YbCl~3~ {#sec2-1}
----------------------------------------------

^175^Yb was produced by thermal neutron bombardment of natural Yb~2~O~3~ target with isotopic purity of 31.8% for ^174^Yb at Tehran Research Reactor (TRR) with neutron flux of 3 × 10^13^ n/cm^2^/s by production scheme; ^174^Yb (n, γ) ^175^Yb → ^175^ Lu (stable). A weighed amount of Yb~2~O~3~ powder was flame sealed into a quartz ampule under vacuum and cold welded into aluminum can. Irradiation was carried out for 7 days. Irradiated Yb~2~O~3~ powder was dissolved in 1 ml of 0.1 M HCl by gentle warming. The resultant solution was evaporated to near dryness and reconstituted in 1 ml of double-distilled water. For radionuclidic purity determination, the samples were checked by gamma-ray spectroscopy on an HPGe detector. The radiochemical purity of ^175^YbCl~3~ was checked using Whatman no. 3 chromatography paper (was obtained from Maidstone, UK) in NH~4~OH:MeOH:H~2~O (1:10:20) system.

Synthesis of TTHMP {#sec2-2}
------------------

The experimental procedure for the synthesis of TTHMP ligand was in accordance with other bisphosphonates as reported. For synthesis of TTHMP, a quantity of 0.48 g (3.3 mmol) of triethylenetetramine was dissolved in 0.75 mL of concentrated HCl and a concentrated aqueous solution of 1.62 g (20 mmol) of phosphorous acid. The resulting solution was heated to reflux temperature and 3.2 mL of 37% aqueous formaldehyde solution (40 mmol) was added dropwise in the course of 1 h to the refluxing solution and refluxing was continued for another 1 h. Chemical structure of TTHMP is shown in [Figure 1](#F1){ref-type="fig"}.

![Chemical structure of ligand](IJNM-29-135-g001){#F1}

Radiolabeling of TTHMP with ^175^YbCl~3~ {#sec2-3}
----------------------------------------

^175^YbCl~3~ (2.85 mCi) dissolved in 0.1 mL of acidic medium (0.1 M HCl) was transferred to a 2 mL vial and the mixture was evaporated by slight warming under a nitrogen flow. Volumes of TTHMP solution (10 mg/mL) were added to activity containing vials. The mixtures were stirred at room temperature for up to 30-60 min. The active solution was checked for radiochemical purity three times for every 2 h by instant thin layer chromatography (ITLC). The pH of final solution was 7.5-8 and then filtered through a 0.22 μm millipore filter for sterilization.

Stability of ^175^Yb-TTHMP complex {#sec2-4}
----------------------------------

Frequent analyses have been performed using Whatman no. 3 chromatography paper in NH~4~OH:MeOH:H~2~O (1:10:20) system to determine the stability of the ^175^Yb-TTHMP.

Serum stability studies {#sec2-5}
-----------------------

The stability of ^175^Yb-TTHMP solution (200 μCi, 50 μl) was checked in presence of freshly prepared human serum (150 μl) at 37°C and was frequently tested for 2 days using above mentioned chromatography system.

Biodistribution studies in rats {#sec2-6}
-------------------------------

In order to investigate biodistribution of ^175^Yb-TTHMP, the data for biodistribution of free ytterbium cation in animals should be obtained. Biodistribution studies of ^175^Yb cation and ^175^Yb-TTHMP were carried out in rats weighing 200-250 g with three rats for each time point. The prepared formulation (150-200 μl, 100-150 μCi) were injected through the tail vein of the rats. The rats were sacrificed post-anesthesia at 2, 4, and 48 h and 4 and 8 days post injection. The tissues and organs were excised and the activity associated with each organ was measured in a NaI (Tl) scintillation counter. For each time interval three rats were used. Distribution of the activity in different organs was calculated as percentage of injected activity per gram of organ (ID/g%).

RESULTS AND DISCUSSION {#sec1-3}
======================

Production of ^175^Yb {#sec2-7}
---------------------

Around 1.3-1.5 GBq/g (35-40 mCi/mg) of ^175^Yb activity was obtained from natural Yb~2~O~3~ target neutron bombarding. Irradiation of natural Yb~2~O~3~ target also results in the formation of ^169^Yb and ^177^Lu as radionuclidic impurities. A typical gamma-ray spectrum of irradiated ytterbium is shown in [Figure 2](#F2){ref-type="fig"}. The observed photo peaks correspond to the photo peaks of ^175^Yb (113, 286, and 396 keV), ^169^Yb (63, 110, 130, 177,198, 261, and 307 keV), and ^177^Lu (208 and 112 keV).

![The high-purity germanium (HPGe) spectrum for Yb-175](IJNM-29-135-g002){#F2}

Labeling optimization studies {#sec2-8}
-----------------------------

In order to obtain the highest labeling yield, a quantitative study was performed using amount of ^175^YbCl~3~ with different molar ratio of TTHMP at room temperature (25°C). The results are shown in [Table 1](#T1){ref-type="table"}.

###### 

The effect of various molar ratios of Yb:TTHMP

![](IJNM-29-135-g003)

Stability of ^175^Yb-TTHMP in final formulation {#sec2-9}
-----------------------------------------------

The stability of the ^175^Yb-TTHMP complex prepared under optimized reaction conditions was studied and it was observed that the complex has excellent stability at room temperature. The complex remained stable to the extent of 98% up to 8 days. The ^175^Yb^3+^ remained at the origin (R~f~ = 0.0-0.1) and the ^175^Yb-TTHMP complex migrates with the solvent to higher Rf (R~f~ = 0.8).

Biodistribution studies {#sec2-10}
-----------------------

The tissue distribution of ^175^YbCl~3~ and ^175^Yb-TTHMP determined in rats over 8 days is shown in Figures [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}, respectively. Specific activity of different organs was calculated as the percentage of injected dose per gram using NaI (Tl) detector. It can be seen from [Figure 3](#F3){ref-type="fig"} accumulation of free Yb^3+^ cation in the vital organs, that is, kidney, liver, lung, spleen, and heart are appreciable. [Figure 4](#F4){ref-type="fig"} demonstrates favorable features of ^175^Yb-TTHMP; such as, significant bone uptake-retention and rapid blood clearance.

![Percentage of injected dose per gram of ^175^YbCl~3~ in rats](IJNM-29-135-g004){#F3}

![Percentage of injected dose per gram of ^175^Yb-triethylenetetramine hexamethylene phosphonic acid (TTHMP) in rats](IJNM-29-135-g005){#F4}

For the better comparison of two sample\'s behavior, vital organ uptake for free Yb-175 and ^175^Yb-TTHMP are described. [Figure 5](#F5){ref-type="fig"} demonstrates the blood accumulation from 2 h to 8 days. Because of the intravenous injection of solutions, accumulation of activities in blood is in the highest value at first 2 h and then ^175^YbCl3 and ^175^Yb-TTHMP are washed out from the circulation after 2 h, although the mechanisms of washout from blood are different.

![Comparative blood activity for ^175^Yb-TTHMP and ^175^YbCl~3~ in rats](IJNM-29-135-g006){#F5}

[Figure 6](#F6){ref-type="fig"} demonstrates the bone accumulation from 2 h to 8 days. ^175^Yb-TTHMP complex was rapidly taken up in the bone in 4 h after injection (ID/g% = 2.29) and remained almost constant up to 8 days (ID/g% = 2.85). Instead, uptake of the free Yb-175 increased slightly, but never exceeded 2%.

![Comparative bone activity for ^175^Yb-TTHMP and ^175^YbCl~3~ in rats](IJNM-29-135-g007){#F6}

In the case of the kidney, ^175^Yb-TTHMP is rapidly taken up in bone and the trapping continues and almost no blood circulation is observed. The concentration of ^175^Yb-TTHMP in kidney decreased from (ID/g% = 0.18) in 2 h to (ID/g% = 0.12) in 4 h and after 8 days it was negligible. But free ^175^Yb as a water-soluble cation is washed out through kidney in 8 days \[[Figure 7](#F7){ref-type="fig"}\].

![Comparative kidney activity for ^175^Yb-TTHMP and ^175^YbCl~3~ in rats](IJNM-29-135-g008){#F7}

Yb^3+^ cation being transferred by serum metalloproteinase accumulates in liver and is excreted through hepatobiliary excretion route, leading to reduction in liver accumulation, while ^175^Yb-TTHMP has almost no liver accumulation. This is a major advantage as a therapeutic radiopharmaceutical due to the possibility of increasing the maximum inject able dose \[[Figure 8](#F8){ref-type="fig"}\].

![Comparative liver activity for ^175^Yb-TTHMP and ^175^YbCl~3~ in rats](IJNM-29-135-g009){#F8}

CONCLUSION {#sec1-4}
==========

From the animal tests and quality control data results, ^175^Yb-TTHMP shows suitable features to be used as alternative radiopharmaceutical for bone pain palliation. It was prepared and quality control was carried out in optimized conditions. Labeling and quality control took 1 h, radiochemical purity was higher than 95%, and radionuclidic purity was acceptable. The radiolabeled complex was stable in human serum for least 2 days. The biodistribution data on normal rats showed at least 70% accumulation of ^175^Yb-TTHMP is in the bone tissues. Although it is not available in high specific activities, the uni-elemental abundance makes it an accessible and inexpensive radionuclide; and the obtained specific activity is enough for radiolabeling of small molecules at radiopharmaceutical grades. Therefore, in this situation and considering all of the excellent features of ^175^Yb-TTHMP, this radiopharmaceutical can be used for effective management of bone pain palliation of skeletal metastases.

Animal rights {#sec2-11}
-------------

The institutional and international guide for the care and use of laboratory animals was followed. See the experimental part for details.
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